Chemoproteomics Market Analysis: How The Industry Is Evolving Toward A $3.36 Billion Future
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Chemoproteomics Market Size Forecast: How Big Could The Market Get By 2030?
The chemoproteomics market has experienced significant growth in recent years. Its valuation is projected to rise from $1.77 billion in 2025 to $2.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.5%. This historical expansion can be attributed to factors such as increased investment in proteomics research, a surge in pharmaceutical R&D activities, the adoption of advanced mass spectrometry techniques, heightened efforts in drug discovery and biomarker identification, and the broadening of academic and research institutes.
The chemoproteomics market size is set for significant expansion in the coming years. It will grow to $3.36 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. This forecasted growth is primarily driven by factors such as the increasing integration of artificial intelligence into proteomics analysis, a heightened demand for high-throughput chemoproteomics platforms, an elevated emphasis on personalized medicine, the enlargement of contract research organizations, and the wider embrace of multi-omics strategies. Key developments expected during this period involve a greater uptake of activity-based protein profiling, an increased need for quantitative proteomics techniques, the deeper integration of structural proteomics approaches, the broadening of affinity-based protein profiling applications, and a stronger emphasis on both label-free and isotope labeling methods.
Get A Free Sample Report With In-Depth Market Insights:
Chemoproteomics Market Growth Factors Behind Sustained Expansion
The rising need for individualized medical approaches is anticipated to fuel the expansion of the chemoproteomics market in the future. Individualized medicine involves healthcare interventions and treatments customized for each patient, considering their unique genetic composition, biological markers, and specific ailment traits. The heightened requirement for personalized medicine stems from breakthroughs in genomic technologies and advanced molecular diagnostics, which empower medical professionals to adjust treatments precisely to a patient’s genetic blueprint, thus enhancing treatment results. Chemoproteomics facilitates personalized medicine through pinpointing protein-drug interactions unique to each patient and their biomarker profiles, thereby allowing for customized therapies that optimize effectiveness and reduce undesirable side effects. A notable example is that in February 2024, the Personalized Medicine Coalition, a US-based non-profit group, reported that the Food and Drug Administration sanctioned 16 novel personalized treatments for individuals with rare diseases in 2023, an increase from six in 2022, comprising seven cancer medications and three for other conditions. Consequently, the increasing demand for personalized medicine is a key impetus behind the growth of the chemoproteomics market.
Chemoproteomics Market Segment Performance And Emerging Opportunities
The chemoproteomics market covered in this report is segmented –
1) By Technology: Activity Based Protein Profiling, Quantitative Proteomics, Structural Proteomics, Affinity Based Protein Profiling, Label Free And Isotope Labeling Techniques
2) By Product Type: Reagents And Kits, Instruments, Software, Services
3) By Application: Drug Discovery, Target Identification And Validation, Biomarker Discovery, Proteome Profiling, Other Application
4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End-User
Subsegments:
1) By Activity Based Protein Profiling: Enzyme Activity Profiling, Covalent Probe Profiling, Targeted Activity Profiling, Functional Protein Profiling
2) By Quantitative Proteomics: Stable Isotope Labeling, Isobaric Tag Labeling, Label Free Quantification, Metabolic Labeling
3) By Structural Proteomics: X Ray Crystallography, Nuclear Magnetic Resonance, Cryogenic Electron Microscopy, Hydrogen Deuterium Exchange
4) By Affinity Based Protein Profiling: Protein Ligand Interaction, Antibody Based Capture, Small Molecule Affinity Capture, Protein Complex Isolation
5) By Label Free and Isotope Labeling Techniques: Label Free Mass Spectrometry, Isotope Coded Affinity Tagging, Dimethyl Labeling, Tandem Mass Tag Labeling
Chemoproteomics Market Industry Trends Fueling Future Revenue Growth
Companies operating in the chemoproteomics market are concentrating on developing innovative solutions, such as live cell target engagement platforms, to speed up drug discovery and enhance early stage efficacy prediction. A live cell target engagement platform is a technology designed to measure how drug candidates interact with their molecular targets within living cells in real time, offering more precise and physiologically relevant data compared to traditional in vitro assays. For instance, in September 2025, LeadArt Biotechnologies Inc., a US-based biotechnology research company, unveiled its INTRAP platform, a next-generation live-cell target engagement and chemoproteomics system, at AHeDD 2025. This platform integrates chemoproteomics, automation, and AI to analyze drug-target interactions directly inside living cells. This functionality allows researchers to more efficiently identify and optimize drug candidates, especially for challenging or “undruggable” targets. By supplying real-time, physiologically relevant data, INTRAP seeks to improve early-stage success rates and accelerate the entire drug discovery process.
Chemoproteomics Market Key Players Shaping Industry Direction
Major companies operating in the chemoproteomics market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., Shimadzu Corporation, PerkinElmer Inc., Bruker Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Evotec SE, Promega Corporation, Cell Signaling Technology Inc., Seer Inc., ChomiX Biotech Inc., Abcam plc, Creative Proteomics Inc., MtoZ Biolabs Inc., Allumiqs Corporation, Dalriada Drug Discovery Ltd., MS Bioworks LLC.
View The Full Chemoproteomics Market Report:
Chemoproteomics Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the chemoproteomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemoproteomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
